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Observations from each trajectory are also 
interesting (Table 1). An FEV1 that is normal at 
cohort inception without COPD at the final exam-
ination (trajectory 1) seems reasonable. An FEV1 
that is normal or low at cohort inception with 
concomitant COPD at the final examination 
(trajectories 3 and 4) does also, especially con-
sidering the authors’ careful description of the 
participants assigned to trajectory 4. The long-
term, 20% increase in FEV1 reported for partici-
pants in trajectory 2, though, is noteworthy.2 
The stable ratio of FEV1 to forced vital capacity 
(FVC) in participants in trajectory 2 (79±12 vs. 
76±5) would imply a similar increase in FVC. 
Can the authors provide a second conclusion from 
their study?
Mark Moran, M.D.
55 Orinda View Rd. 
Orinda, CA 
mark@moranadvisors.com
No potential conflict of interest relevant to this letter was re-
ported.
1. Lange P, Celli B, Agustí A, et al. Lung-function trajectories 
leading to chronic obstructive pulmonary disease. N Engl J Med 
2015;373:111-22.
2. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric refer-
ence values from a sample of the general U.S. population. Am J 
Respir Crit Care Med 1999;159:179-87.
DOI: 10.1056/NEJMc1510089
The Authors Reply: Moran focuses on the 
course of FEV1 in participants in trajectory 2, the 
persons with small lungs in whom COPD did not 
develop during the approximately 22 years of 
follow-up. Yet, we disagree with Moran’s conclu-
sion. In this trajectory, there was no real increase 
in the FEV1. The FEV1 declined very little (approx-
imately 2 ml per year, as shown in Fig. 1 of our 
article), and the mean FEV1 was 2.6 liters both at 
baseline and at the end of the follow-up (Table 3 
of our article). The impression of an increase of 
20% is therefore erroneous, since it is not possi-
ble to assess the decline in FEV1 according to the 
percentage of the predicted value. In other words, 
one can say that the “increased” FEV1 in the per-
centage of the predicted value in this trajectory 
between the onset and the end of observation is 
caused by the fact that persons in this trajectory 
lost their FEV1 much more slowly than would be 
expected according to prediction equations for 
normal FEV1.
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Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
To the Editor: Lal et al. (May 28 issue)1 report 
on the efficacy of an adjuvanted subunit vaccine 
against herpes zoster. The case-definition algo-
rithm included polymerase-chain-reaction (PCR) 
assays targeting varicella–zoster virus (VZV) and 
an ascertainment committee that reviewed digi-
tal photographs and clinical notes to classify each 
suspected case. The members of the committee 
were unaware of the PCR results and study-group 
assignments.
However, the primary efficacy end point could 
not be determined for 33 cases of suspected zoster 
(Fig. S1 in the Supplementary Appendix, available 
with the full text of the article at NEJM.org). It 
would be of interest to identify the proportion of 
participants who received vaccine in this group of 
33 cases, since these data might provide evidence 
of a modified presentation of the rash. Milder, 
atypical (or modified) rashes have been described 
predominantly in previously vaccinated persons 
presenting with smallpox, measles, or primary 
VZV infection associated with partial immuni-
ty.2-5 Could this phenomenon be associated with 
this zoster vaccine as well, albeit not a live one?
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To the Editor: The Zoster Efficacy Study in 
Adults 50 Years of Age or Older (ZOE-50), a ran-
domized, placebo-controlled, phase 3 study con-
ducted by Lal and colleagues, showed 97.2% 
 efficacy of a subunit vaccine containing VZV glyco-
protein E and the AS01B  adjuvant system (HZ/su) 
in preventing herpes zoster. We note that 337 
participants (4.4%) received only one dose of vac-
cine, and 277 participants (3.6%) received only 
one dose of placebo. Can the authors provide the 
reasons why these participants did not receive a 
second dose?
Earlier findings from a phase 2 study showed 
significantly higher humoral and CD4+ T-cell 
responses to two doses of this vaccine than to a 
single dose.1 In another study, the maximum 
humoral immune responses occurred in young 
adults after one dose; in other age groups, im-
munologic responses were higher after a second 
dose, but they were not statistically significant.2
Given previous immunologic responses to this 
vaccine and the high efficacy of two doses, it 
would be of interest to know the efficacy of a 
single dose. Although it was not a stated pri-
mary or secondary objective, and the precision is 
expected to be lower owing to the sample size, 
can the authors provide the efficacy of a single 
dose of this vaccine on the basis of data on the 
recipients of one dose in this study?
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The Authors Reply: George and Lawrence ask 
whether the inconclusive cases in our ZOE-50 
study might indicate that there were modified 
presentations of zoster in persons who received 
the investigational HZ/su vaccine. Since this 
study is ongoing and treatment-group assign-
ments remain blinded, we currently do not know 
whether inconclusive cases occurred in HZ/su 
recipients. However, cases of zoster may be in-
conclusive for reasons unrelated to the nature of 
the rash. For example, PCR testing, the primary 
method for verifying zoster cases, was not pos-
sible for 21 of 33 inconclusive cases because of 
the lack of samples. Also, for many inconclusive 
cases, inadequate clinical information, often 
because of the late presentation of participants 
at the study site, made case ascertainment dif-
ficult.
Fielding and Lambert note that a small pro-
portion of participants in our study received a 
single dose of vaccine or placebo. Eighteen par-
ticipants did not receive the second dose because 
a suspected zoster case occurred between the 
first and second doses. However, since the study 
remains blinded, we cannot yet provide reasons 
for nonreceipt of the second dose.
Fielding and Lambert further note that an 
earlier study showed strong humoral responses to 
a single dose of HZ/su in young adults.1 Subse-
quent studies, however, provide a stronger basis 
for comparing one-dose immunogenicity with 
two-dose immunogenicity.2,3 In these studies, 
HZ/su was assessed in larger, more representa-
tive older adult populations, and a second dose 
was shown to enhance both cellular and hu-
moral responses. An ongoing parallel efficacy 
study, Zoster Efficacy Study in Adults 70 Years of 
Age or Older (ZOE-70), involves more than 14,000 
older adults. When the study is completed, com-
bined data from ZOE-50 and ZOE-70 can be used 
to provide an estimate of the efficacy of one dose. 
However, the power to evaluate the efficacy of 
one dose would be limited by the low number 
of zoster cases in participants receiving a single 
dose and the limited 2-month window in which 
most of these cases are likely to occur. We 
therefore expect that efficacy data based on 
this brief follow-up will provide only limited 
insight into the clinical value of single-dose 
vaccination.
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Short-Course Antimicrobial Therapy for Intraabdominal Infection
To the Editor: Sawyer and colleagues (May 21 
issue)1 report the findings of the Study to Opti-
mize Peritoneal Infection Therapy (STOP-IT) trial. 
A strength of this study was the freedom afford-
ed to clinicians in the selection of antibiotic regi-
mens, as long as the choice met Surgical Infec-
tion Society–Infectious Diseases Society of America 
(SIS–IDSA) guidelines. International guidelines 
vary with respect to recommended regimens for 
intraabdominal infection2,3; this variation partly 
reflects differences in patterns of antimicrobial 
resistance worldwide.
Data on the most commonly used antimicro-
bial agents and culture isolates in the trial are 
presented in Table S1 in the Supplementary 
Appendix (available with the full text of the article 
at NEJM.org), but it would be of value to under-
stand these in more detail, to help clinicians, in 
particular those outside North America, translate 
the findings of the trial into clinical practice.
Given the flexibility afforded with respect to 
first-line therapy, can the authors provide more 
details on which specific empirical regimens 
were used in the study? In particular, it would be 
informative to know the percentage of culture 
isolates that were susceptible to the initial anti-
microbial regimen and how frequently therapy 
was switched because of resistance. Given the 
brief duration of treatment in the experimental 
group, was a mismatch between the choice of 
the initial antimicrobial drug and organism sus-
ceptibility associated with worse outcomes?
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To the Editor: Sawyer et al. find that a short 
course of antimicrobial therapy (4±1 calendar 
days) was as efficient as an antibiotic treatment 
guided by a clinical approach with respect to the 
occurrence of surgical-site infections, recurrent 
intraabdominal infections, or death. We would 
like to focus on some points of concern. As de-
signed in the study, this strategy cannot be ex-
trapolated to patients with an inadequate source-
control procedure. The authors did not report the 
proportion of included patients with severe sep-
sis, septic shock, or both; mortality among these 
patients is close to 25%.1 The mortality in this 
study (0.8 to 1.2%) suggests that only patients 
with uncomplicated intraabdominal infections 
were involved. Can the study findings be extrap-
olated to antifungal therapy in Candida albicans 
infections (11.2% of the isolated pathogens in 
the control group and 7.0% of the isolated patho-
gens in the experimental group in this study), 
given that in such patients the isolation of can-
dida has been considered to be a risk factor for 
death? 2 In any case, this study should lead phy-
sicians to be more cost-effective in their daily 
practice.
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